Literature DB >> 22505629

Unique O-methoxyethyl ribose-DNA chimeric oligonucleotide induces an atypical melanoma differentiation-associated gene 5-dependent induction of type I interferon response.

Sebastien A Burel1, Todd Machemer, Frank L Ragone, Hiroki Kato, Patrick Cauntay, Sarah Greenlee, Aneeza Salim, William A Gaarde, Gene Hung, Raechel Peralta, Susan M Freier, Scott P Henry.   

Abstract

Antisense oligonucleotides (ASO) containing 2'-O-methoxyethyl ribose (2'-MOE) modifications have been shown to possess both excellent pharmacokinetic properties and robust pharmacological activity in several animal models of human disease. 2'-MOE ASOs are generally well tolerated, displaying minimal to mild proinflammatory effect at doses far exceeding therapeutic doses. Although the vast majority of 2'-MOE ASOs are safe and well tolerated, a small subset of ASOs inducing acute inflammation in mice has been identified. The mechanism for these findings is not clear at this point, but the effects are clearly sequence-specific. One of those ASOs, ISIS 147420, causes a severe inflammatory response atypical of this class of oligonucleotides characterized by induction in interferon-β (IFN-β) at 48 h followed by acute transaminitis and extensive hepatocyte apoptosis and necrosis at 72 h. A large number of interferon-stimulated genes were significantly up-regulated in liver as early as 24 h. We speculated that a specific sequence motif might cause ISIS 147420 to be mistaken for viral RNA or DNA, thus triggering an acute innate immune response. ISIS 147420 toxicity was independent of Toll-like receptors, because there was no decrease in IFN-β in Toll/interleukin-1 receptor-domain-containing adapter-inducing IFN-β or Myd88-deficient mice. The involvement of cytosolic retinoic acid-inducible gene (RIG)-I-like pattern recognition receptors was also investigated. Pretreatment of mice with melanoma differentiation-associated gene 5 (MDA5) and IFN-β promoter stimulator-1 ASOs, but not RIG-I or laboratory of genetics and physiology 2 (LGP2) ASOs, prevented the increase in IFN-β and alanine aminotransferase induced by ISIS 147420. These results revealed a novel mechanism of oligonucleotide-mediated toxicity requiring both MDA5 and IPS-1 and resulting in the activation of the innate immune response.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22505629     DOI: 10.1124/jpet.112.193789

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  13 in total

1.  Hybrid Mouse Diversity Panel Identifies Genetic Architecture Associated with the Acute Antisense Oligonucleotide-Mediated Inflammatory Response to a 2'-O-Methoxyethyl Antisense Oligonucleotide.

Authors:  Elaine Pirie; Patrick Cauntay; Wuxia Fu; Shayoni Ray; Calvin Pan; Aldonis J Lusis; Jill Hsiao; Sebastien A Burel; Padma Narayanan; Rosanne M Crooke; Richard G Lee
Journal:  Nucleic Acid Ther       Date:  2019-08-01       Impact factor: 5.486

Review 2.  Injection site reactions after subcutaneous oligonucleotide therapy.

Authors:  Leonie van Meer; Matthijs Moerland; Jolie Gallagher; Martijn B A van Doorn; Errol P Prens; Adam F Cohen; Robert Rissmann; Jacobus Burggraaf
Journal:  Br J Clin Pharmacol       Date:  2016-05-31       Impact factor: 4.335

3.  Identification of small molecules with type I interferon inducing properties by high-throughput screening.

Authors:  Luis Martínez-Gil; Juan Ayllon; Mila Brum Ortigoza; Adolfo García-Sastre; Megan L Shaw; Peter Palese
Journal:  PLoS One       Date:  2012-11-07       Impact factor: 3.240

4.  Strategies for In Vivo Screening and Mitigation of Hepatotoxicity Associated with Antisense Drugs.

Authors:  Piotr J Kamola; Klio Maratou; Paul A Wilson; Kay Rush; Tanya Mullaney; Tom McKevitt; Paula Evans; Jim Ridings; Probash Chowdhury; Aude Roulois; Ann Fairchild; Sean McCawley; Karen Cartwright; Nigel J Gooderham; Timothy W Gant; Kitty Moores; Stephen A Hughes; Mark R Edbrooke; Kenneth Clark; Joel D Parry
Journal:  Mol Ther Nucleic Acids       Date:  2017-07-08       Impact factor: 8.886

5.  Intracerebroventricular Administration of a 2'-O-Methyl Phosphorothioate Antisense Oligonucleotide Results in Activation of the Innate Immune System in Mouse Brain.

Authors:  Lodewijk J A Toonen; João Casaca-Carreira; Maria Pellisé-Tintoré; Hailiang Mei; Yasin Temel; Ali Jahanshahi; Willeke M C van Roon-Mom
Journal:  Nucleic Acid Ther       Date:  2018-03-22       Impact factor: 5.486

6.  DNA/RNA heteroduplex oligonucleotide for highly efficient gene silencing.

Authors:  Kazutaka Nishina; Wenying Piao; Kie Yoshida-Tanaka; Yumiko Sujino; Tomoko Nishina; Tsuyoshi Yamamoto; Keiko Nitta; Kotaro Yoshioka; Hiroya Kuwahara; Hidenori Yasuhara; Takeshi Baba; Fumiko Ono; Kanjiro Miyata; Koichi Miyake; Punit P Seth; Audrey Low; Masayuki Yoshida; C Frank Bennett; Kazunori Kataoka; Hidehiro Mizusawa; Satoshi Obika; Takanori Yokota
Journal:  Nat Commun       Date:  2015-08-10       Impact factor: 14.919

7.  Hepatotoxicity of high affinity gapmer antisense oligonucleotides is mediated by RNase H1 dependent promiscuous reduction of very long pre-mRNA transcripts.

Authors:  Sebastien A Burel; Christopher E Hart; Patrick Cauntay; Jill Hsiao; Todd Machemer; Melanie Katz; Andy Watt; Huynh-Hoa Bui; Husam Younis; Mahyar Sabripour; Susan M Freier; Gene Hung; Amy Dan; T P Prakash; Punit P Seth; Eric E Swayze; C Frank Bennett; Stanley T Crooke; Scott P Henry
Journal:  Nucleic Acids Res       Date:  2015-11-08       Impact factor: 16.971

8.  Ribonuclease H1-dependent hepatotoxicity caused by locked nucleic acid-modified gapmer antisense oligonucleotides.

Authors:  Takeshi Kasuya; Shin-Ichiro Hori; Ayahisa Watanabe; Mado Nakajima; Yoshinari Gahara; Masatomo Rokushima; Toru Yanagimoto; Akira Kugimiya
Journal:  Sci Rep       Date:  2016-07-27       Impact factor: 4.379

9.  Chemical Modification of CRISPR gRNAs Eliminate type I Interferon Responses in Human Peripheral Blood Mononuclear Cells.

Authors:  Mollie S Schubert; Edward Cedrone; Barry Neun; Mark A Behlke; Marina A Dobrovolskaia
Journal:  J Cytokine Biol       Date:  2018-01-29

10.  Antisense oligonucleotide treatment produces a type I interferon response that protects against diet-induced obesity.

Authors:  Kristin M McCabe; Joanne Hsieh; David G Thomas; Matthew M Molusky; Liana Tascau; Jun B Feranil; Li Qiang; Anthony W Ferrante; Alan R Tall
Journal:  Mol Metab       Date:  2020-01-30       Impact factor: 7.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.